GI Surgery – Bariatric Surgery
RCT: Effect of banded Roux-en-Y gastric bypass versus sleeve gastrectomy on diabetes remission at 5 years among patients with obesity and type 2 diabetes.
24 Jun, 2022 | 11:10h | UTCEffect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial – Diabetes Care (link to abstract – $ for full-text)
RCT: Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y Gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity.
23 Jun, 2022 | 10:17h | UTCEffect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Commentary on Twitter
10-year follow-up of the SLEEVEPASS RCT: both sleeve and gastric bypass resulted in good #weightloss. Reflux was more prevalent after sleeve. The incidence of #Barrettesophagus was much lower than in previous trials, and similar after both procedures. https://t.co/zRLzB6Nf7a
— JAMA Surgery (@JAMASurgery) June 22, 2022
Safety of bariatric surgery in patients with previous acute coronary events or heart failure: nationwide cohort study.
21 Jun, 2022 | 10:44h | UTC
Commentary on Twitter
#Bariatric surgery improves metabolic health of patients, but what are the risks if they have had MI before surgery?
National dataset matched 16000 pts🇸🇪
Heart dis assoc w/🔼 cardiac events post op, plus 🔼risk of SBO and stricture.#SoMe4Surgery https://t.co/iHsZiHIgdG pic.twitter.com/v2SXMpcZd3— BJS Open (@BjsOpen) June 17, 2022
#ADA2022 – Retrospective Cohort Study: Association of bariatric surgery with cancer risk and mortality in adults with obesity.
6 Jun, 2022 | 11:54h | UTCAssociation of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity – JAMA (free for a limited period)
Editorial: Bariatric Surgery and Cancer Risk – JAMA (free for a limited period)
News Release: Weight loss with bariatric surgery cuts the risk of developing cancer and death from cancer – Cleveland Clinic
Commentaries on Twitter
In this study, among adults with #obesity, #bariatricsurgery compared with no surgery was associated with a significantly lower incidence of obesity-associated #cancer and cancer-related mortality. https://t.co/x2gz3RUdra
— JAMA (@JAMA_current) June 3, 2022
Retrospective cohort presented at the @AmDiabetesAssn: incidence rate of 3.0 events vs 4.6 events per 1,000 person-years, resp, & a 32% reduced risk for developing obesity-related cancer following weight loss via surgery. @ClevelandClinic
https://t.co/6jLDmhgJbR @JAMA_current
— Karl Nadolsky (@DrKarlNadolsky) June 4, 2022
ERAS Guidelines for perioperative care in elective abdominal and pelvic surgery at primary and secondary hospitals in low–middle-income countries.
1 Jun, 2022 | 12:08h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
M-A: Endoscopic bariatric and metabolic therapies and their effects on metabolic syndrome and non-alcoholic fatty liver disease.
27 May, 2022 | 11:31h | UTC
M-A: Bariatric surgery and cardiovascular disease.
6 Mar, 2022 | 23:34h | UTC
Cohort study: In patients who underwent bariatric surgery, those submitted to gastric bypass were slightly more likely to remain free of obesity-related medications during follow-up compared with those who underwent sleeve gastrectomy.
18 Jan, 2022 | 09:31h | UTCMedication Use for Obesity-Related Comorbidities After Sleeve Gastrectomy or Gastric Bypass – JAMA Surgery (link to abstract – $ for full-text)
Commentary: Gastric Bypass Tied to Modest Shift in Need for Comorbidity Meds – MedPage Today (free registration required)
Commentary on Twitter
Among patients taking medications for obesity-related conditions before bariatric surgery, gastric bypass and sleeve gastrectomy both had high rates of medication discontinuation after surgery, however gastric bypass was slightly more effective. https://t.co/JrIaYk9dZT pic.twitter.com/BAbaGINCpb
— JAMA Surgery (@JAMASurgery) January 12, 2022
ERAS Guidelines for perioperative care in bariatric surgery.
16 Jan, 2022 | 23:21h | UTCRelated: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Commentary on Twitter
#VisualAbstract ➡️ Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update@Jasosamd @iss_sic
🆓🔗https://t.co/HknWwLUjCZ pic.twitter.com/amhszadwup— WJS (@WorldJSurg) January 5, 2022
Cohort Study: Patients who achieved weight loss through bariatric surgery may have lower risk for severe Covid-19 compared to patients who did not have surgical intervention for their obesity.
14 Jan, 2022 | 08:32h | UTCCommentaries:
Is COVID-19 the Newest Comorbidity of Obesity Mitigated by Bariatric Surgery? – JAMA Surgery
Can weight loss help protect against Covid-19? – CNN
RCT: Adjustable intragastric balloon resulted in significant weight loss at 32 weeks, but intolerance caused early removal of the device in 17% of patients, and device-related serious adverse events were observed in 4% of patients.
17 Nov, 2021 | 08:26h | UTCAdjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
In this trial, when an adjustable intragastric balloon was combined with lifestyle modification in adults with obesity, significant weight loss was achieved and maintained for 6 months following device removal. https://t.co/jg7z5ldeC7 #GITwitter pic.twitter.com/Pi9PVAeWzo
— The Lancet (@TheLancet) November 16, 2021
Cohort study: In patients with nonalcoholic steatohepatitis and obesity, bariatric surgery was associated with lower risk of incident major adverse liver outcomes and major adverse cardiovascular events.
12 Nov, 2021 | 10:24h | UTCAssociation of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis – JAMA (free for a limited period)
Editorial: Bariatric Surgery as a Strategy for Improving Outcomes in Nonalcoholic Steatohepatitis – JAMA (free for a limited period)
Commentary on Twitter
Study found, among patients with nonalcoholic steatohepatitis and obesity, bariatric surgery, vs nonsurgical management, was associated with a significantly lower risk of incident major adverse liver outcomes and major adverse cardiovascular events https://t.co/Ps23yfjncq
— JAMA (@JAMA_current) November 11, 2021
Large observational study suggests sleeve gastrectomy may be safer compared to gastric bypass in patients with severe obesity.
7 Oct, 2021 | 10:26h | UTCComparative Safety of Sleeve Gastrectomy and Gastric Bypass Up to 5 Years After Surgery in Patients With Severe Obesity – JAMA Surgery (free for a limited period)
Commentaries:
Compared to What?—Novel Methods to Approach Randomization for Long-term Bariatric Surgery Outcomes – JAMA Surgery (free for a limited period)
Of two common weight loss surgeries, one is safer but less effective – Michigan Medicine
Related:
Cohort study: comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass
Cohort study: interventions and operations 5 years after bariatric surgery
Randomized trial: gastric bypass superior to sleeve gastrectomy for remission of type 2 diabetes
Research: laparoscopic sleeve gastrectomy vs laparoscopic roux-en-y gastric bypass
Commentary on Twitter
Study suggests that the safety benefits of sleeve gastrectomy persist up to 5 years after surgery; this information may help patients and surgeons make informed treatment decisions https://t.co/JuRQGh3byz
— JAMA Surgery (@JAMASurgery) October 6, 2021
Different risks and benefits leading to similar costs after sleeve gastrectomy and Roux-en-Y gastric bypass.
12 Sep, 2021 | 21:37h | UTCOriginal study: Comparison of 4-Year Health Care Expenditures Associated With Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy – JAMA Network Open
Commentary on Twitter
Cohort study found that 4-year healthcare expenditures associated with Roux-en-Y gastric bypass (RYGB) surgery and sleeve gastrectomy (SG) did not differ in Ontario, Canada. https://t.co/pegVdcwgJG
— JAMA Network Open (@JAMANetworkOpen) September 9, 2021
AGA clinical practice update on evaluation and management of early complications after bariatric/metabolic surgery.
24 Aug, 2021 | 09:02h | UTC
Commentary on Twitter
August's Essential Reading article is a Clinical Practice Update on evaluation and management of early complications after bariatric/metabolic surgery @AmerGastroAssn https://t.co/mm8qSkR95y pic.twitter.com/6vsI3qGv2I
— CGH (@AGA_CGH) July 28, 2021
Podcast | Bariatric Surgery for the Internist – Patient selection, perioperative management, and post-operative care.
25 May, 2021 | 08:37h | UTC#275 Bariatric Surgery for the Internist with Dr. Vivian Sanchez – The Curbsiders
M-A: Metabolic–bariatric surgery is associated with increased long-term survival in adults with obesity, the effects being more pronounced for people with pre-existing diabetes
11 May, 2021 | 09:11h | UTCAssociation of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants – The Lancet (link to abstract – $ for full-text)
RCT: Closure vs. non-closure of mesenteric defects during laparoscopic gastric bypass surgery – In this single-center trial, routine closure of the mesenteric defects in laparoscopic Roux-en-Y gastric bypass with clips was associated with a lower rate of internal herniation
28 Apr, 2021 | 08:04h | UTCRandomized clinical trial on closure versus non-closure of mesenteric defects during laparoscopic gastric bypass surgery – British Journal of Surgery (link to abstract – $ for full-text)
Commentary on Twitter
Free in February's BJS: Randomized clinical trial on closure versus non-closure of mesenteric defects during laparoscopic gastric bypass surgery https://t.co/rFl0WdZI6v @AmyLightnerMD @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @robhinchliffe1 @young_bjs pic.twitter.com/YnwUwDCWhB
— BJS (@BJSurgery) April 10, 2021
AGA recommends intragastric balloons as an additional weight loss option for obese patients
23 Apr, 2021 | 08:10h | UTCOriginal article: AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity – Gastroenterology
M-A: Portal venous system thrombosis after bariatric surgery
21 Apr, 2021 | 06:16h | UTCPortal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis – Surgery (link to abstract – $ for full-text)
The first modified Delphi consensus statement on sleeve gastrectomy
9 Mar, 2021 | 02:09h | UTCThe first modified Delphi consensus statement on sleeve gastrectomy – Surgical Endoscopy
Laparoscopic Roux-en-Y gastric bypass vs. laparoscopic sleeve gastrectomy: 5-year outcomes of merged data from two randomized clinical trials
2 Mar, 2021 | 01:27h | UTCVisual abstract: Merged SLEEVEPASS and SM-BOSS trials
Study: Unhealthy alcohol use common after bariatric surgery
26 Feb, 2021 | 08:14h | UTCCommentaries: Unhealthy Alcohol Use—A Common Iatrogenic Complication of Bariatric Surgery – JAMA Network Open AND Bariatric Surgery May Increase Risk of Unhealthy Alcohol Use – Psychiatric News Alert AND Bariatric Surgery Ups Risk of Alcohol Abuse – Physician’s Weekly
Commentary on Twitter
Our team’s analysis of VA bariatric surgery outcomes. Alcohol use increased 3–8 years after surgery. The benefits far outweigh the risks, but we need to support our patients long-term. @davearterburn @NeilFlochMD https://t.co/QpGHeRrI9l via @JAMANetworkOpen part of @JAMANetwork
— Luke Funk, MD, MPH (@lmfunk2) December 26, 2020
10-year follow up of a randomized trial shows metabolic surgery is more effective than conventional medical therapy for the control of type 2 diabetes
26 Jan, 2021 | 00:44h | UTCMetabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial – The Lancet (link to abstract – $ for full-text)